Tenpoint Therapeutics and Visus Therapeutics Merge, Strengthening Ophthalmic Therapeutics Pipeline

Tenpoint Therapeutics和Visus Therapeutics融合，加强眼科治疗管道

December 13, 2024

2024年12月13日

Tenpoint Therapeutics Ltd. and Visus Therapeutics Inc. have officially merged, combining their respective ophthalmic therapeutic assets to form a unified entity focused on addressing ocular conditions associated with aging, including presbyopia, cataracts, and geographic atrophy.

Tenpoint Therapeutics Ltd.和Visus Therapeutics Inc.正式合并，合并各自的眼科治疗资产，形成一个统一的实体，专注于解决与衰老相关的眼部疾病，包括老视，白内障和地理萎缩。

Key Therapeutics in the Combined Portfolio

组合组合中的关键疗法

BRIMOCHOL PF: A Promising Presbyopia Treatment

BRIMOCHOL PF：一种有前途的老视治疗方法

A cornerstone of the merged portfolio is BRIMOCHOL PF, an innovative, once-daily eye drop for correcting presbyopia. The therapy combines:

合并投资组合的基石是BRIMOCHOL PF，这是一种创新的每日一次的眼药水，用于矫正老视。该疗法结合了：

• Carbachol: A miotic agent.

•卡巴胆碱：一种缩瞳剂。

• Brimonidine: An alpha2-agonist.

•溴莫尼定：一种α2激动剂。

This combination is designed to improve efficacy and duration while minimizing ocular redness. BRIMOCHOL PF is slated for a New Drug Application (NDA) submission in the first half of 2025, with U.S. commercialization planned by 2026.

这种组合旨在提高疗效和持续时间，同时最大程度地减少眼部发红。BRIMOCHOL PF计划于2025年上半年提交新药申请（NDA），美国计划于2026年实现商业化。

Additional Therapeutic Programs from Tenpoint

Tenpoint的其他治疗计划

The merger also incorporates Tenpoint’s advanced-stage programs:

此次合并还纳入了Tenpoint的高级阶段计划：

• TPT-161: A small molecule targeting cataract formation.

•TPT-161：一种靶向白内障形成的小分子。

• TPT-005: A cell therapy for retinal pigment epithelium (RPE) replacement to treat geographic atrophy.

•TPT-005：视网膜色素上皮（RPE）替代治疗地理萎缩的细胞疗法。

Leadership Team

领导团队

Henric Bjarke, CEO

Henric Bjarke，首席执行官

Henric Bjarke has been appointed as CEO of the combined company. With extensive leadership experience in biopharmaceuticals, particularly in ophthalmology, Bjarke expressed enthusiasm for the newly merged entity:

亨利·比亚克（HenricBjarke）被任命为合并后公司的首席执行官。凭借在生物制药领域，特别是眼科领域的丰富领导经验，比亚克对新合并的实体表示了热情：

“As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with BRIMOCHOL PF, a near-term therapeutic medicine for presbyopia, alongside other innovative therapies to treat cataract and geographic atrophy. With our combined teams, we have the right expertise to develop and successfully launch innovative products with the potential to be first and best in class in ophthalmic medicines.”.

“当我们重新启动Tenpoint作为与Visus的联合实体时，我们很高兴能够领导一个强大的眼科管道，从BRIMOCHOL PF开始，这是一种治疗老视的短期治疗药物，以及其他治疗白内障和地理萎缩的创新疗法。通过我们的联合团队，我们拥有正确的专业知识来开发并成功推出创新产品，有可能成为眼科药物领域的一流和最佳产品。”。

David Guyer, MD, Chairman of the Board

David Guyer，医学博士，董事会主席

Dr. David Guyer will serve as Chairman of the Board, bringing significant expertise to the company’s strategic direction:

David Guyer博士将担任董事会主席，为公司的战略方向带来重要的专业知识：

“The merger of Tenpoint and Visus is a pivotal moment in the evolution of both companies. As Board Chair, I am excited about the opportunity to collaborate with the new leadership team to commercialize BRIMOCHOL PF and advance innovative products into clinical development to meet unmet needs in ocular diseases.”.

“Tenpoint和Visus的合并是两家公司发展的关键时刻。作为董事会主席，我很高兴有机会与新的领导团队合作，将BRIMOCHOL PF商业化，并将创新产品推进临床开发，以满足眼部疾病未满足的需求。”。

Financial and Strategic Plans

财务和战略计划

The company plans to initiate a crossover financing round to support ongoing clinical studies and prepare for the commercialization of BRIMOCHOL PF.

该公司计划发起一轮交叉融资，以支持正在进行的临床研究，并为BRIMOCHOL PF的商业化做好准备。

Consolidated Mission and Future Goals

综合任务和未来目标

By merging late-stage and early-stage programs, the combined company aims to:

通过合并后期和早期项目，合并后的公司旨在：

• Advance BRIMOCHOL PF and additional therapies through clinical and regulatory milestones.

•通过临床和监管里程碑推进BRIMOCHOL PF和其他疗法。

• Address critical unmet needs in ocular conditions related to aging.

•解决与衰老有关的眼部疾病的关键未满足需求。

• Plan for the introduction of innovative ophthalmic treatments to the market.

•计划将创新眼科治疗引入市场。

This merger represents a transformative step for both companies, uniting their strengths to drive innovation and deliver cutting-edge solutions in ophthalmology.

这一合并对两家公司来说都是一个变革性的步骤，将它们的优势结合起来，推动创新并提供眼科领域的前沿解决方案。